Combining Fluorescent Cell Sorting and Single B Cell Amplification to Screen the Monoclonal Antibody Gene against Human Glypican-1 in Pancreatic Cancer

Mi Huang,1,2 Yingying Ma,1,2 Xiaoyan Gao,1,2 Xinyang Li,1,3 Quan Ding,2 Chuxin Liu,1 Xiaopan Liu,1 Hang Zhang,2 and Naibo Yang1,2,3,4

1BGI-Shenzhen, Shenzhen, Guangdong 518083, China
2BGI-Wuhan, Wuhan 430074, China
3BGI Education Center, University of Chinese Academy of Sciences, Shenzhen, Guangdong 518083, China
4Complete Genomics Inc., San Jose, CA, USA

Correspondence should be addressed to Naibo Yang; yangnaibo@genomics.cn

Received 1 July 2021; Accepted 6 August 2021; Published 6 September 2021

Academic Editor: Muhammad Wasim Khan

Copyright © 2021 Mi Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In this report, one novel method has been developed to screen the monoclonal antibody against human pancreatic cancer biomarker glypican-1 (GPC1) through the combination of fluorescent cell sorting and single B cell amplification. GPC1-positive B cells were sorted out from the peripheral blood mononuclear cells (PBMCs) by fluorescent cell sorting after the GPC1 immunization to the New Zealand white rabbit. Then, total RNA was extracted and reversely transcribed into cDNA, which was used as the template, and the variable region sequences of both heavy and light chains were amplified from the same B cell. Next, their recombinant antibody was expressed and purified from the human 293T cell after the antibody gene amplification and expression vector construction. The enzyme-linked immunosorbent assay (ELISA) and flow cytometry assays were used to determine the antibody affinity. The antibody named GPC-12 that we screened and obtained was proven to have natural heavy-light chain pairing information, and it was highly specific to the GPC1 antigen, and the affinity could reach $1 \times 10^{-7}$ M. Overall, an effective and novel method has been successfully developed to screen the antibody by combining the fluorescent cell sorting and single-cell amplifying technologies, which was proved to be workable in our setting.

1. Introduction

Pancreatic cancer is a malignant gastrointestinal malignancy, with the prognosis being rather grim [1]. In recent years, the incidence of pancreatic cancer has been shown to have an upward trend, and it is predicted that pancreatic cancer causes more than 331,000 deaths every year [2, 3]. Overall survival rate of pancreatic cancer ranked the lowest among all kinds of malignant tumors. The five-year survival rate was only 2%–9%, with an average being no more than 6% [2], and the morbidity/mortality rate was close to 100% [4]. Therefore, it is essential to develop the new diagnostic method for pancreatic cancer, known as the king of cancer, which makes the early diagnosis of pancreatic cancer become possible.

The diagnosis of pancreatic cancer is mainly based on a comprehensive diagnostic method, that is, imaging, tumor markers, and tissue biopsy [5]. However, the diameter of early pancreatic cancer is usually less than two centimeters; and it is confined to the pancreatic parenchyma and does not invade the pancreatic capsule. Traditional imaging methods are not sensitive and specific enough to detect pancreatic cancer lesions. All these make it extremely difficult to measure and detect the pancreatic cancer. Therefore, it is required to develop the novel method to earlier detect the multiple tumor markers, which plays an important role in improving the positive detection rate of cancer patients, cancer screening in high-risk groups without clinical symptoms, and early detection of pancreatic cancer [6, 7].
At present, CA19-9 and CEA are commonly used tumor markers for detection of pancreatic cancer, but the two biomarkers were less specific in that they are also related antigens in other cancers, such as colorectal cancer or ovarian cancer [8, 9]. The positive rate of CA19-9 was over 80%, but the positive rate of CA19-9 in small pancreatic cancer patients was not high (60.7% in adenocarcinoma patients less than 2 cm), while the positive rate of CEA was only 78.9%. Therefore, there is an urgent need to find a more specific antibody for pancreatic cancer, that is to say, a detection reagent with higher diagnostic positive rate, which can be used as a common detection marker for pancreatic cancer [10, 11]. As early as 1998, it has been reported that Glypican-1 (GPC1) was overexpressed in pancreatic cancer cells; and that Glypican-1 could regulate the metastasis and angiogenesis of pancreatic cancer cells, playing a pivotal role in the oncogenesis of pancreatic ductal adenocarcinoma [12]. These previous findings suggest that GPC1 can be a potential diagnostic biomarker. In addition, in 2015, one study reported that GPC1 had nearly 100% sensitivity and specificity in both animal models and clinical patients with pancreatic cancer, being able to accurately detect early pancreatic cancer, indicating that GPC1 has great potential as a tumor marker for early detection of pancreatic cancer [13–15].

Consequently, to screen the monoclonal antibody against human pancreatic cancer biomarker GPC1, in this study, a single B cell clone against human pancreatic cancer GPC1 was sorted out by flow cytometry; and then a natural pair of antibody heavy and light chain sequences were amplified from a single B cell by PCR. In performing PCR, the codons preferred by adult mammalian cells were optimized. After gene synthesis, the expression vector was constructed and transfected into HEK293T cells for expression. The binding activity of antibody to antigen was evaluated by ELISA, and the affinity kinetics between antibody protein and antigen GPC1 were verified by surface plasmon resonance (SPR).

2. Materials and Methods

2.1. Materials. New Zealand white rabbits were purchased and reared in the Food and Drug Safety Evaluation Center of Hubei Province. Sample homogenate device (instrumental model: T10) was purchased from IKA-Werke GmbH & Co. KG (Staufen, Germany). Analytical flow cytometry (CytoFLEX S) was purchased from Beckman Coulter Inc. (Beckman Coulter, Brea, CA, USA). Sorting flow cytometry (MoFlo XDP) was purchased from Beckman Coulter Inc. (Beckman Coulter, Brea, CA, USA). Horizontal hanging basket centrifuge (H1850R) was from Huan Xiangyi, and 1 × RPMI1640 basic medium was purchased from Gibco Company. Fetal bovine serum (FBS) was from HyClone Company. Horseradish peroxidase labeled sheep anti-rabbit IgG was purchased from GeneTex Company. SuperScript II Reverse Transcriptase was purchased from Invitrogen Inc. (Life Technologies, Carlsbad, CA, USA). Fluorescein Isothiocyanate (FITC) was purchased from Sigma Chemical Co. (St. Louis, MO, USA). Ficoll-Paque PREMIUM for PBMC separation was purchased from GE Healthcare (San Diego, CA, USA). D2000 DNA ladder was purchased from Tiangen Biochemical Technology Co., Ltd. (Beijing, China). rTaq enzyme and TA clone are from TaKaRa (TaKaRa, Japan) with pMD18-T vector, E. coli competent cell DH5-alpha, and template switch oligos (TSO). Master Mix was purchased from Kapa Biosystems (Boston, MA, USA). Bovine serum albumin, Triton X-100, Freund’s complete adjuvant, Freund’s incomplete adjuvant, and GPC1 polypeptide were purchased from Sigma Chemical Co. (St. Louis, MO, USA). PCR product purification kit and agarose gel recovery kit were purchased from QIAGEN Company (Germany). pFUSE-Fc mammalian cell expression plasmid was purchased from Invitrogen Inc. (Life, Carlsbad, CA, USA). Commercial anti-GPC1 monoclonal antibodies were purchased from GeneTex (CA, USA).

2.2. Animal Immunization. The experimental animal immunization and blood collection program were approved by the Animal Ethics Committee of Shenzhen Huada Academy of Life Sciences (ethics approval number FT15149). Two New Zealand white rabbits aged 5–6 weeks were immunized by subcutaneous injection on the back. They were immunized once every two weeks, four times in total. 500 μl antigen (200 micrograms of antigen protein dissolved in 500 μl of sterile water to form a solution of 0.4 mg/mL) and 500 μl Freund’s complete adjuvant were used uniformly. The pulp machine emulsified evenly and was used for the first time before immunization. The other three immunizations used a mixture of Freund’s incomplete adjuvant and antigen emulsifies evenly and equally.

2.3. Blood Collection and Cell Separation. Before or two weeks after the final immunization, blood samples were collected from the ear vein of two white rabbits. The serum of 100 μl before and after immunization was used to test the titer of anti-positive antibody. The peripheral blood of a white rabbit with strong immune response was collected and separated by Ficoll lymphocyte gradient centrifugation.

2.4. Detection of Serum and Antibody Titers by ELISA. The antigen was dissolved in coating solution (50 mM Na₂CO₃, pH 9.6) at an appropriate concentration, and 100 μl antigen was added to the corresponding pore overnight at 4°C. The liquid was discarded and the residual liquid was dried, followed by rinsing with the detergent PBST (1 × PBS pH 7.4 plus 0.05% Tween 20, the same as below) three times. Each pore was incubated at 37°C for 1 h with 200 μl blocking solution (3% BSA). The liquid was emptied and the remaining liquid was dried. The washing liquid was used for rinsing three times. Each pore was incubated with 100 μl diluted serum or antibody, at 37°C for 1 hour. The liquid was emptied and the remaining liquid was dried. The washing liquid was used for rinsing three times. Each pore was incubated with 100 μl secondary antibody (1:5000 diluted horseradish peroxidase labeled sheep anti-rabbit IgG) for 1 hour at 37°C. The liquid was emptied and the remaining
Conventional flow cytometry was subjected to the success rate of amplification will be greatly reduced. The washing liquid was used for rinsing five times. The residual liquids in the dry holes were patted, and 100 μl color developing solution was added to each hole, and the color was visualized for 10 minutes without light. Each hole was terminated by adding 50 μl 2M H₂SO₄, and the 450 nm OD value was read immediately.

2.5. Cell Staining and Selection. The 1 mg GPC1 antigen was dissolved in 0.1 M carbonate buffer of 0.5 mL pH 9.0. FITC (sigma F4274) was dissolved with DMSO, and the final concentration of FITC was 1 mg/mL. FITC-DMSO solution was slowly added to antigen solution, and 50 μl FITC-DMSO solution was added to antigen solution. The reaction time was 8 h at 4°C. The reaction was terminated by adding NH₄CL with the final concentration of 50 mM and reacted at 4°C for 2 h. Ultrafiltration removes unreacted FITC.

The isolated rabbit PBMC was suspended to the final volume of 20 μl PBS and 2 μl GPC1-FITC was added. The PBMC was gently vortexed and blended. The light-avoiding reaction lasted 1 hour at room temperature (a small number of cells without GPC1-FITC were reserved as negative control). After the reaction, 1 mL PBS was added; the supernatant was discarded by centrifugation for 5 minutes and precipitated by 1 mL PBS. The supernatant was discarded by centrifugation for 5 minutes and precipitated by 1 mL PBS. The samples were prepared by centrifugation for 5 min at 400 xg, discarding the supernatant, and resuspension precipitation with 500 μl PBS. The density of the samples was about 10⁷/mL.

2.6. Preparation of Cell Lysate. A 4 μl lysate [1.86 μl non-nuclease water, 1 μl Oligo(dT)18 (10 μmol/L), 0.1 μl RNase inhibitor (4 U), and 0.04 μl Triton X-100 (100 mL/L)] was prepared. The lysate was placed in a 0.2 mL PCR tube (8 rows of 96-well plate). The selected cells were directly added to the cell lysate. One tube of negative pore (0 cells, i.e., no cell sorting) was reserved for each row; one tube of positive pore (i.e., 10 cells sorted) was used as control, and 10 tubes of single-cell pore were reserved for each row. Twelve PCR tubes can be selected as one group for each experiment, and the rest can be frozen to −80°C group. After two weeks of use, the success rate of amplification will be greatly reduced.

2.7. Separation of GPC1-FITC-Positive Cells by Flow Cytometry. Conventional flow cytometry was subjected to calibration, and then calibration was undertaken for sorting parameters; the latency value of side fluid flow and droplets were adjusted to make the left bright spot farthest and most concentrated in the side fluid flow window; then the coordinate value of cell sorting around the coordinate window was adjusted to ensure that the sheath fluid can hit the bottom of the PCR tube (cells cannot hit the wall of the side tube; otherwise, it would affect the success rate of amplification). At last, the rate of cell sorting was checked, such as setting 10 cells to be sorted; looking at the actual number of cells under the microscope, more than 90% of the cells were qualified and could be sorted in the next step. After all the above steps were completed, the sorting commenced.

2.8. Cell Lysis and Reverse Transcription. The PCR tube containing lysate was placed in the PCR instrument at 72°C for 3 minutes; the hot cover was set at 75°C for 1 min on ice immediately after lysis and centrifuged at 10,000 r/min for 30 seconds. 6 μl reverse transcription system [2 μl SuperScript II First-Strand Buffer (5×), 2 μl betaine (5 mol/L), 0.9 μl MgCl₂ (100 mmol/L), 0.25 μl DTT (100 mmol/L), 0.1 μl TSO (100 μmol/L), 0.25 μl RNA inhibitor (4 U), and 0.5 μl SuperScript II Reverse Transcriptase (20U)] was prepared. Reverse transcription was performed under the following conditions: 42°C for 90 min, 50°C for 2 min, 42°C for 2 min, 10 cycles, 70°C for 15 min, and 12°C. The DNA was obtained.

2.9. Amplification of the Antibody Sequence. Primer Premier 5 software was used to design primers. The products of single-tube cDNA system obtained by the above methods were used as templates for two rounds of nested PCR. In the first round, Ld primers (rIgH-Ld1, rIgK-Ld1, rIgL-Ld1-1, and rIgL-Ld1-2) and downstream primers of heavy and light chain C region (rIgHG-C1, rIgK-C1, and rIgL-C1) were used to prepare 25 μl PCR system [12.5 μl KAPA ReadyMix (2××), 0.5 μl Ld primers (10 μmol/L), 10 μl reverse transcription products, and 1.5 μl nuclease-free water]. The second round of PCR used FR primers (rIgH-FR1 and rIgK-FR1) and J primers (rIgH-J, rIgK-J-1, rIgL-J-2, and rIgL-J). A 25 μl PCR system [12.5 μl KAPA ReadyMix (2××), 0.5 μl FR primer (10 μmol/L), 0.5 μl J primer (10 μmol/L), 1 μl first-round PCR product, and 10.5 μl ribonuclease-free water] was prepared. The amplification conditions for both rounds of PCR were as follows: 95°C for 3 min, 98°C for 15 s, 60°C for 20 s, 72°C for 2 min, 25 cycles, 72°C for 4 min, and 12°C. The amplification system could be amplified as needed. Here, a nested amplification primer was designed (Table 1), TSO and oligo(dT) primers were used in the reverse transcription stage; Ld and C primers were annealed to the upstream sequence of TSO and the downstream CH1 region of antibody subtypes in the first round of PCR, respectively, and the primers of 10 mm/L were mixed equally; the other primers were the second round of PCR primers.

2.10. TA Cloning, Gene Synthesis, and Expression Vector Construction. 10 g/L agarose gel was used to detect the amplified products of PCR, and the target bands (380 BP) were cut and recovered by gel recovery kit. Then, rTaq enzyme was used to add A to the end of the gel-cut recovery product, and the product was purified by the PCR product purification kit and then linked to the pMD18 T vector overnight at 16°C. The conjugates were transferred into competent cells DH5α and cultured in antibiotic-free Luria-Bertani (LB) medium at 37°C for 1 hour. The conjugates were coated on ampicillin-containing LB solid medium overnight. The next day, the monoclonal colony in good condition was selected for shaking culture for 3 to 5 hours, and then the liquid was sent to Shanghai Shanggong.
Company for DNA sequencing to verify whether the antibody sequence is correct and also to verify whether the expression contains both heavy chain and light chain in the correct pairing. According to the preference of human cell expression system, the codon of the amplified heavy and light chain genes was optimized, and then the whole gene of variable region was synthesized and cloned directly into the commercial mammalian cell expression vector pFUSE-rabbit Fc, which contained the Fc constant region of rabbit antibody.

2.11. Expression of Mammalian Cells and Purification of the Antibody. Trypsinase digestive cells were counted and cultured overnight at 37°C and 5% CO₂, and the confluence of cells was 70%–80% at transfection. The plasmid was diluted with a certain volume of Opti-MEM (Invitrogen 11058-021), carefully mixed, and labeled as liquid A. The transfection reagent PEI (Polyscience 23966-2) was diluted with the same volume of Opti-MEM, named liquid B. The mass ratio of plasmid to PEI was 1:2. It was kept at room temperature for 15 minutes. Liquid B was slowly added to liquid A and it was mixed. It was kept at room temperature for 20 minutes. The DNA-PEI mixture was slowly added to the cell culture medium and it was gently mixed. 48 hours after transfection, the supernatant was collected and centrifuged for 5 minutes to remove the cells. The supernatant was centrifuged for 10 minutes to remove the cell debris. The antibody was purified by affinity purification column coupled with GPC1 antigen.

2.12. Antigen-Antibody Binding Kinetics (Affinity Test). The GPC1 antigen was dissolved in the coating solution (50 mM Na₂CO₃, pH 9.6) at an appropriate concentration, and 100 μL antigen was added to the corresponding pore for overnight stay at 4°C. The liquid was emptied and the remaining liquid was washed three times. Each pore was incubated at 37°C for 1 hour with 100 μL diluted antibody. The liquid was emptied and the remaining liquid was dried. The washing liquid was used for rinsing three times. Each pore was incubated with 100 μL secondary antibody (1:5000 diluted horseradish peroxidase labeled sheep anti-rabbit IgG) for 1 hour at 37°C. The liquid was emptied and the remaining liquid was dried. The washing liquid was used for rinsing five times. The residual liquid in the dry hole was patted, adding 100 μL color developing solution to each hole, and coloring at 37°C for 5 minutes. Each hole was added with 50 μL 2 M HCL to stop the color rendering and 450 nm OD value was read immediately.

2.13. Detection of Antibody Binding to Natural GPC1 on the Cell Surface. MDA-MB-231 (China Typical Culture Preservation Center) in logarithmic growth phase was digested into single-cell suspension, counted, and centrifuged to remove the medium. Cell suspension was separated into three centrifugal tubes according to 50 μL/tube with proper volume of PBS suspension cells. No. 1 was without antibody, No. 2 was added with 0.5 μL positive GPC1 antibody (GeneTex GTX42664), and No. 3 was added with 1 μL purified GPC1 antibody and incubated at room temperature for 30 minutes. Each tube was centrifuged with 1 mL PBS for 5 min at 300 × g for supernatant. 1 mL PBS suspension cells were precipitated and centrifuged for 5 min at 300 × g, and then the supernatant was discarded twice. The 50 μL PBS suspended cells were precipitated and incubated at room temperature for 30 minutes with the corresponding fluorescent labeled antibody. Each tube was centrifuged with 1 mL PBS for 5 min at 300 × g for supernatant for three times. Flow detection was done on computer.

2.14. Statistical Analysis. All data were analyzed using SPSS 21.0 statistical software. The data were expressed as mean ± standard deviation. One-way ANOVA (Bonferroni) was used for comparisons among multiple groups. Tukey's post hoc test was used for pairwise comparisons of the mean values between multiple groups. Independent-sample t-test was used to analyze the difference between two groups where the data had normal distribution. P < 0.05 was considered to be statistically significant.

3. Results

3.1. Detection of the Serum-Positive Conversion Titer. To make the titer of the antibodies we produced clear, ELSIA was performed. As shown in Table 2, the blank group refers to the blank control without serum and with 100 μL PBS. The negative group was the negative control with 100 μL serum before immunization. The immune group refers to the serum diluted by 1:100 dilution to 1:32000, and the positive/negative ratio was >8 (generally, the value was greater than 4; that is to say, the immune serum was positive), which

**Table 1: Primer name and sequence.**

| Name     | Sequence (5’ to 3’) |
|----------|---------------------|
| TSO[12]  | AAGCAGTGGTATCAACGCAGTAGG+G⁺ |
| Oligo(dT)18 | TTTTTTTTTTTTTTTTTT |
| rlgH-Ld1 | CTTCCTCGGTCGCTGTC |
| rlgH-FR1 | CACTCACCCTGACAYCTCTGGG |
| rlgK-Ld1 | CTTGCTGGGGCTCCTG |
| rlgK-FR1 | GCTGTGGGAGGCACAGTCAC |
| rlgL-Ld1 | CCTCACAGTCCTGGCTCACTGCACA |
| rlgL-J   | CGACGACCACCTYGGTC |
| rlgK-J-1 | TGATTTCACCTTGTTGC |
| rlgK-J-2 | CGACGACCACCTYGGTC |
| rlgL-J   | CTGTCAGGTCAGCTGGTC |
| rlgHG-C1 | GAAGACTGAYGGAAGCCTAGT |
| rlgK-C1  | GGTGGGAAAGATGAGCAGCAGT |
| rlgL-C1  | CCTCAGGAGGGCGGGRAACA |
To stain fluorescently.

3.2. Cell Staining and Flow Cytometry. To stain fluorescently the cells of interest, GPC1-FITC was used. As shown in Figure 1(a), NC- was not stained with GPC1-FITC for immunized rabbit lymphocytes, NC+ was stained with GPC1-FITC for immunized rabbit lymphocytes, GPC1 was not stained with GPC1-FITC for immunized rabbit lymphocytes, and GPC1+ was stained with GPC1-FITC for immunized rabbit lymphocytes. It can be seen that the lymphocyte without GPC1-FITC staining was in the same fluorescence intensity range regardless of immunization, and the lymphocyte without GPC1-FITC staining also showed positive deviation and nonspecific binding, but the fluorescence intensity was lower than that of immunized rabbit lymphocyte. Therefore, this part was the cells that need to be further sorted, as shown in Figure 1(b).

3.3. Amplification and Sequencing of the Monocyte Antibody Gene. To purify the cells that were fluorescently stained with GPC1-FITC, cell sorting was employed based on flow cytometry. As shown in Figure 2, one cell was selected from lane 2 to lane 15 as a PCR template, from 18 to 19 as a positive control, 10 cells were selected as templates, and 20 to 21 as a negative control, which was no cells. The size of target protein was about 380 bp. It can be seen that, in lanes 11, 12, and 14, as well as in positive control, there was the size of target band. The corresponding PCR products of lanes 11, 12, and 14 were gelatinized, cloned, and sequenced by TA. By comparing the results of sequencing, it was found that lane 12 was a rabbit antibody sequence and paired with light chain. This sequence was named GPC1-12. The next step was to construct GPC1-12 on the vector for expression.

3.4. ELISA Detection of Antibody Transfection Supernatant. To understand the titer of antibody we produced, ELISA was undertaken. As shown in Figure 3(a), bovine serum albumin (BSA) and cell culture medium (Medium) were negative controls, and positive control (abbreviated as PC) was polyclonal antibodies purified from rabbit serum by affinity purification column. The expression of GPC1-12 was detected in the supernatant of transfection. The next step was affinity purification of the supernatant.

3.5. Affinity Determination of the Purified Antibody. In order to further verify the binding activity of the purified antibody and GPC1 antigen, we carried out ELISA binding test. The initial concentration of the purified antibody was 100 μg/mL, and then it was diluted twice. The results showed that, as shown in Figure 3(b), compared with the uncoated antigen group and blank control, GPC1-12 purified antibody was shown to have specific binding performance with GPC1 antigen.

3.6. Detection of Antibody Binding Abilities to Natural Surface Protein. To verify the affinity of antibody we generated, evaluation was performed with flow cytometry. As shown in Figure 4, GPC1-12 monoclonal antibody (blue solid line) could bind well to cells but had a significant positive deviation from the negative control (red line).

4. Discussion

Pancreatic cancer is a highly malignant tumor, ranking near the eighth place among all kinds of lethal tumors. In addition, its cure rate and five-year survival rate are very low. Therefore, early diagnosis of pancreatic cancer is of particularly important, and there is a huge potential demand in patients with pancreatic cancer. Biomarker-based early diagnosis of cancer has always been prevailing, such as CA19-9-based diagnostic kit, but its specificity and sensitivity for the diagnosis of pancreatic cancer still need to be improved. It has been reported that GPC1 has a higher specificity for pancreatic cancer than CA19-9 [7]. The aim of this study was to develop and establish one effective method to screen out the more specific diagnostic antibodies for pancreatic cancer GPC1 by means of flow cytometry and single-cell amplification.

Similar to our previous report regarding single-cell study [16], three batches of rabbit single B cells were selected, 17 antibody sequences against human GPC1 were screened, and using these sequences, expression vectors were constructed, and antibodies were expressed. GPC1-12 was turned out to be the best antibody sequence in this screening process in our setting, which guaranteed the affinity of antibody antigen and the relative expression quantity. It was proved to be higher than those of other clones. There might be several reasons for the low expression of other antibodies. Firstly, after many rounds of PCR reaction, mutation could occur to some key bases of the antibody gene, which would greatly affect its expression level; secondly, the commercial expression vector pc-DNA serial vectors might have low expression efficiency, and other expression vectors could be replaced, such as pc-FUSE-rabbit Fc might have low expression efficiency, and other expression vectors could be replaced, such as pc-DNA serial vectors.

Traditional methods of antibody preparation mainly include hybridoma cell method and phage display method [17]. Outside of animal immunity, both of them have a lot of library building and screening work, which lasts for several months or even half a year. In this study, the period.

| Rabbit number | Detection of the antigen | Blank group | Negative group (1:10000) | Immune group (1:10000) | Immune group (1:40000) | Immune group (1:160000) | Immune group (1:320000) |
|---------------|--------------------------|-------------|--------------------------|------------------------|------------------------|--------------------------|--------------------------|
| Rabbit 1      | GPC1                     | 0.070       | 0.111                    | 2.922                  | 2.132                  | 1.424                    | 0.987                    |
| Rabbit 2      | GPC1                     | 0.062       | 0.082                    | 2.536                  | 2.071                  | 1.054                    | 0.663                    |

Table 2: Detection of the serum-positive conversion titer.
of antibody screening using immune antigens can be directly and remarkably shortened with the aid of flow cytometric cell sorting; moreover, the B cell clones isolated need not be cultured and expanded any more. The advantage of the methods we established here is that the amplification of antibody heavy chain and light chain genes can be directly obtained. It can directly obtain the matching information of antibody heavy chain and light chain, thus eliminating the cumbersome steps of cDNA library establishment and cell culture, therefore substantially greatly improving the efficiency of screening antibodies.

Figure 1: Cell fluorescent staining and sorting of single cell by flow cytometry. (a) Cell fluorescent staining; NC− means lymphocytes without GPC1-FITC staining. The lymphocytes were sampled from rabbits without immunization. NC+ means lymphocytes stained with GPC1-FITC. The lymphocytes were sampled from rabbits without immunization. GPC1− represents lymphocytes that were not stained with GPC1-FITC from immunized rabbits; GPC1+ denotes lymphocytes that were stained with GPC1-FITC from immunized rabbits. (b) B cell sorting by flow cytometry. GPC1+ cells were all that we want which were sorted by flow cytometry.

Figure 2: Electrophoresis of single-cell amplification. As shown in the electrophoretic gel, lanes 2–15 denote that only one cell sorted was used as the PCR template; lanes 18 and 19 were set as the positive control, where 10 cells sorted were utilized as the PCR template; lanes 20 and 21 were set as the negative control in which no cell was used in PCR. The gene of interest was around 380 bp. Lanes 11, 12, and 14, as well as positive controls, in which the bands of interest can be visibly achieved can be seen.
Based on the sequence of the antibody obtained in this experiment, the experiment that follows need to be considered, including the following: Firstly, the screened antibodies could be used to prepare early diagnostic kits for pancreatic cancer based on ELISA or flow cytometry. Secondly, with going deep in the research work, it has been reported that exosomes played an increasingly important role in the diagnosis and treatment of diseases, especially in cancer [18]. Considering this, the antibodies we screened can be used to isolate the antigen-specific exosomes by flow cytometry for subsequent clinical diagnosis and treatment. In conclusion, the method we established and developed here obtained highly specific antibody sequences and was able to substantially shorten the experimental cycle, which
would be also suitable for screening other targets one is interested in.

**Abbreviations**

GPC1: Glypican-1  
PBMCs: Peripheral blood mononuclear cells  
ELISA: Enzyme-linked immunosorbent assay  
FITC: Fluorescein-5-isothiocyanate  
DMSO: Dimethyl sulfoxide  
PBS: Phosphate-buffered saline  
PCR: Polymerase chain reaction.

**Data Availability**

All data generated or analyzed during this study are truthfully presented. Relevant data are available upon request.

**Ethical Approval**

The animal procedures were approved by the Institutional Animal Care and Use Committee at BGI, Shenzhen. All procedures were in compliance with the guidance released by the Care and Use of Laboratory Animals Regulations of BGI, Shenzhen.

**Disclosure**

Mi Huang and Yingying Ma are the co-first authors.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Authors’ Contributions**

Mi Huang and Yingying Ma contributed equally to this work. Both performed the experiments involved and collected the data. XYL and QD provided help in statistical analysis. CXL and XPL did some favor in cell culture and reagents purchase. YL and HZ contributed to the writing and revising of the manuscript. NY conceived the idea and was in charge of the whole project.

**Acknowledgments**

This work was supported by the Shenzhen Science and Technology Innovation Committee (no. JCYJ20160531194232631).

**References**

[1] S. A. El-Zahaby, Y. S. R. Elnaggar, and O. Y. Abdallah, “Reviewing two decades of nanomedicine implementations in targeted treatment and diagnosis of pancreatic cancer: an emphasis on state of art,” *Journal of Controlled Release*, vol. 293, pp. 21–35, 2019.

[2] P. Maisonneuve, “Epidemiology and burden of pancreatic cancer,” *La Presse Médicale*, vol. 48, no. 3, pp. e113–e123, 2019.

[3] W. Chen, R. Zheng, P. D. Baade et al., “Cancer statistics in China, 2015,” *CA: A Cancer Journal for Clinicians*, vol. 66, no. 2, pp. 115–132, 2016.

[4] T. Kamisawa, L. D. Wood, T. Itoi, and K. Takaori, “Pancreatic cancer,” *The Lancet*, vol. 388, no. 10039, pp. 73–85, 2016.

[5] B. Zhou, J.-W. Xu, Y.-G. Cheng et al., “Early detection of pancreatic cancer: where are we now and where are we going?” *International Journal of Cancer*, vol. 141, no. 2, pp. 231–241, 2017.

[6] M. R. Young, J.-W. Xu, Y.-G. Cheng et al., “Early detection of pancreatic cancer: where are we now and where are we going?” *International Journal of Cancer*, vol. 141, no. 2, pp. 231–241, 2017.

[7] M. Herreros-Villanueva and L. Bujanda, “Glypican-1 in exosomes as biomarker for early detection of pancreatic cancer,” *Annals of Translational Medicine*, vol. 4, no. 4, p. 64, 2016.

[8] R. Peltonen, P. Österlund, M. Lempinen, A. Nordin, U.-H. Stenman, and H. Isoniemi, “Postoperative CEA is a better prognostic marker than CA19-9, hCGβ or TATI after resection of colorectal liver metastases,” *Tumor Biology*, vol. 40, no. 1, 2018.

[9] J. Guo, J. Yu, X. Song, and H. Mi, “Serum CA125, CA199 and CEA combined detection for epithelial ovarian cancer diagnosis: a meta-analysis,” *Open Medicine*, vol. 12, no. 1, pp. 131–137, 2017.

[10] J. Song, L. J. Sokoll, J. J. Pasay et al., “Identification of serum biomarker panels for the early detection of pancreatic cancer,” *Cancer Epidemiology Biomarkers & Prevention*, vol. 28, no. 1, pp. 174–182, 2019.

[11] X. Zou, J. Wei, Z. Huang et al., “Identification of a six-miRNA panel in serum benefitting pancreatic cancer diagnosis,” *Cancer Medicine*, vol. 8, no. 6, pp. 2810–2822, 2019.

[12] J. Kleeff, T. Ishiwata, A. Kumbasar et al., “The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer,” *Journal of Clinical Investigation*, vol. 102, no. 9, pp. 1662–1673, 1998.

[13] C.-y. Zhou, Y.-p. Dong, X. Sun et al., “High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma,” *Cancer Medicine*, vol. 7, no. 11, pp. 5525–5533, 2018.

[14] W. Qiu, H. Zhang, X. Chen et al., “A GPC1-targeted and gemcitabine-loaded biocompatible nanoplatform for pancreatic cancer multimodal imaging and therapy,” *Nano- medicine*, vol. 14, no. 17, pp. 2339–2353, 2019.

[15] S. A. Melo, L. B. Luecke, C. Kahler et al., “Glypican-1 identifies cancer exosomes and detects early pancreatic cancer,” *Nature*, vol. 523, no. 7559, pp. 177–182, 2015.

[16] X. Li, P. Yang, and N. Yang, “A set of methods of amplification of human monoclonal antibody heavy and light chain genes from one single B cell,” *Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi*, vol. 34, no. 4, pp. 367–372, 2018.

[17] A. F. U. H. Saeed, R. Wang, S. Ling, and S. Wang, “Antibody engineering for pursuing a healthier future,” *Frontiers in Microbiology*, vol. 8, p. 495, 2017.

[18] S. Kamerkar, V. S. LeBlu, H. Sugimoto et al., “Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer,” *Nature*, vol. 546, no. 7659, pp. 498–503, 2017.